3TC: combination trial stopped early as clinical benefit shown
- PMID: 11363752
3TC: combination trial stopped early as clinical benefit shown
Abstract
AIDS: The DSMB (data safety monitoring board) stopped a major trial of 3TC (lamivudine) when the ongoing study showed a significant reduction in the rates of death or disease progression when 3TC was added to other antiretroviral regimens. The trial was discontinued by unanimous consent. A separate pediatric trial is now underway, monitoring the effects of 3TC in delaying disease progression or death in children.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical